drugset / Trial / NCT03914794
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Phase 2
Completed
30 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
Timeline
- Start
- 2020-10-02
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | — | Oral |